Asset profile
Mirogabalin
Small molecule
Evidence outlook · lead readout
NCT04094662 · Diabetic Peripheral Neuropathic Pain
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04094662: This was a randomized, triple-blind, placebo-controlled trial of 393 patients. Mirogabalin produced a statistically significant reduction in daily pain scores compared with placebo, meeting the trial's primary goal, though the size of the benefit and its statistical margin were modest.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
15 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 14 same-indication; 5 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mirogabalin: this drug | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Crisugabalin | Phase 3 | Small molecule | α2δ-1 subunit of voltage-gated calcium channels | ||
| Capsaicin (Qutenza) | Approved | Small molecule | TRPV1 (transient receptor potential vanilloid 1) channel | ||
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | ||
| Pregabalin | Approved | Small molecule | α2δ subunit of voltage-gated calcium channels | ||
| Suzetrigine | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| Tapentadol | Approved | Small molecule | Mu-opioid receptor and norepinephrine transporter (NET) | ||
| HL-1186 | Phase 2/3 | Small molecule | — | ||
| HRS-2129 | Phase 2/3 | Small molecule | — | ||
| JMKX000623 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| LY4065967 | Phase 2 | Small molecule | Angiotensin II type 2 receptor (AT2R) (antagonist) | ||
| NRD135S.E1 | Phase 2 | Small molecule | — | ||
| Pilavapadin | Phase 2 | Small molecule | AP2-associated kinase 1 (AAK1) | ||
| Pirenzepine (topical) | Phase 2 | Small molecule | Muscarinic acetylcholine receptor (M3), Muscarinic M1 receptor (antagonist) | ||
| VX-993 | Phase 2 | Small molecule | Voltage-gated sodium channel NaV1.8 | ||
| AJH-2947 | Phase 1 | Small molecule | — |
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
March 2027 (1)
What to watch
June 2027 (1)
What to watch
October 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.